OCUL vs. ARQT, INVA, KNSA, SUPN, PLRX, APLS, RNA, IMVT, ACLX, and MRUS
Should you be buying Ocular Therapeutix stock or one of its competitors? The main competitors of Ocular Therapeutix include Arcutis Biotherapeutics (ARQT), Innoviva (INVA), Kiniksa Pharmaceuticals (KNSA), Supernus Pharmaceuticals (SUPN), Pliant Therapeutics (PLRX), Apellis Pharmaceuticals (APLS), Avidity Biosciences (RNA), Immunovant (IMVT), Arcellx (ACLX), and Merus (MRUS). These companies are all part of the "medical" sector.
Arcutis Biotherapeutics (NASDAQ:ARQT) and Ocular Therapeutix (NASDAQ:OCUL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, community ranking, earnings, institutional ownership, analyst recommendations, risk and profitability.
In the previous week, Arcutis Biotherapeutics had 1 more articles in the media than Ocular Therapeutix. MarketBeat recorded 5 mentions for Arcutis Biotherapeutics and 4 mentions for Ocular Therapeutix. Arcutis Biotherapeutics' average media sentiment score of 0.81 beat Ocular Therapeutix's score of 0.37 indicating that Ocular Therapeutix is being referred to more favorably in the news media.
Ocular Therapeutix received 376 more outperform votes than Arcutis Biotherapeutics when rated by MarketBeat users. Likewise, 69.85% of users gave Ocular Therapeutix an outperform vote while only 62.50% of users gave Arcutis Biotherapeutics an outperform vote.
Arcutis Biotherapeutics has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. Comparatively, Ocular Therapeutix has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500.
Ocular Therapeutix has lower revenue, but higher earnings than Arcutis Biotherapeutics. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Ocular Therapeutix has a net margin of -192.61% compared to Ocular Therapeutix's net margin of -204.35%. Arcutis Biotherapeutics' return on equity of -76.64% beat Ocular Therapeutix's return on equity.
Arcutis Biotherapeutics currently has a consensus price target of $23.57, suggesting a potential upside of 134.08%. Ocular Therapeutix has a consensus price target of $15.83, suggesting a potential upside of 87.82%. Given Ocular Therapeutix's higher possible upside, analysts clearly believe Arcutis Biotherapeutics is more favorable than Ocular Therapeutix.
59.2% of Ocular Therapeutix shares are owned by institutional investors. 9.5% of Arcutis Biotherapeutics shares are owned by company insiders. Comparatively, 5.5% of Ocular Therapeutix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
Ocular Therapeutix beats Arcutis Biotherapeutics on 12 of the 18 factors compared between the two stocks.
Get Ocular Therapeutix News Delivered to You Automatically
Sign up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OCUL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ocular Therapeutix Competitors List
Related Companies and Tools
Free OCUL Stock Alerts